Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,650 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Clinical trials
11,128 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,492)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06784206 | Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06667167 | First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy | recruiting | Phase 2 | 21 | Nir PeledOTHER | 1 | Jan 17, 2025 |
| NCT06779539 | Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 33 | West China HospitalOTHER | 0 | Jan 17, 2025 | clinicaltrials |
| NCT06780839 | Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD | not yet recruiting | Phase 2 | 70 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06581419 | A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors | recruiting | Phase 1 / Phase 2 | 78 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06775275 | A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC | recruiting | Phase 2 | 60 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06775483 | Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study | not yet recruiting | Phase 2 | 220 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 0 | Jan 15, 2025 | clinicaltrials |
| NCT06773156 | Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer | enrolling by invitation | Phase 2 | 37 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06422403 | A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers(VALUE-CHECK) | recruiting | Phase 2 | 360 | National University Hospital, SingaporeOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06769295 | A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC | recruiting | Phase 2 | 28 | Sichuan UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06769971 | Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC | recruiting | Phase 2 | 80 | Sichuan UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT04440735 | A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Kahr MedicalINDUSTRY | 1 | Jan 9, 2025 | clinicaltrials |
| NCT05688280 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS(INJECTABL-1) | active not recruiting | Phase 1 / Phase 2 | 42 | Immunophotonics, Inc.INDUSTRY | 5 | Jan 8, 2025 | clinicaltrials |
| NCT06090266 | A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | recruiting | Phase 1 / Phase 2 | 168 | OncoResponse, Inc.INDUSTRY | 1 | Jan 7, 2025 | clinicaltrials |
| NCT05417321 | A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 80 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 2 | Jan 3, 2025 | clinicaltrials |
| NCT05712902 | Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6) | active not recruiting | Phase 2 | 104 | Dizal PharmaceuticalsINDUSTRY | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06672068 | A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC | not yet recruiting | Phase 2 | 60 | TYK Medicines, IncINDUSTRY | 0 | Dec 30, 2024 | clinicaltrials |
| NCT06751849 | Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment | recruiting | Phase 2 | 10 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06751901 | Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment | recruiting | Phase 2 | 10 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06752408 | Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer(ANOTHER) | not yet recruiting | Phase 2 | 316 | Peking Union Medical College HospitalOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06749691 | Liposomal Irinotecan and Apatinib in ES-SCLC(LIAES) | recruiting | Phase 2 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06749860 | Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression | recruiting | Phase 2 | 58 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06749886 | An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting | recruiting | Phase 2 | 22 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06746870 | A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer | not yet recruiting | Phase 2 | 148 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 0 | Dec 24, 2024 | clinicaltrials |
| NCT05877430 | Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | recruiting | Phase 1 / Phase 2 | 160 | CJ Bioscience, Inc.INDUSTRY | 2 | Dec 20, 2024 | clinicaltrials |
| NCT06532591 | Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC | recruiting | Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06281678 | A Study of IBI363 in Subjects with Advanced Solid Malignancies | recruiting | Phase 2 | 178 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Dec 19, 2024 | clinicaltrials |
| NCT05879068 | A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC | active not recruiting | Phase 2 | 99 | Biotheus Inc.INDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06467617 | Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC | recruiting | Phase 2 | 35 | Beijing Chest Hospital, Capital Medical UniversityOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06734182 | Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer(neovision) | recruiting | Phase 2 | 25 | Guangdong Provincial People's HospitalOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06728852 | Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study(Vigor) | recruiting | Phase 2 | 32 | Li-kun ChenOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06724263 | A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors | not yet recruiting | Phase 2 | 120 | Tasly Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06718309 | Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC | recruiting | Phase 2 | 40 | First People's Hospital of HangzhouOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT06706713 | Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer | recruiting | Phase 2 | 200 | BeBetter Med IncINDUSTRY | 1 | Nov 26, 2024 | clinicaltrials |
| NCT05128487 | A Study of NDI 1150-101 in Patients With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 106 | Nimbus Saturn, Inc.INDUSTRY | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06702826 | Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases | recruiting | Phase 2 | 20 | Rongrong ZhouOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT04699721 | Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC | active not recruiting | Phase 2 | 60 | Xiangya Hospital of Central South UniversityOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT06700421 | Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis | active not recruiting | Phase 2 | 32 | Wei ZhouOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT06698965 | Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin | recruiting | Phase 2 | 52 | Shanghai Chest HospitalOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT01553942 | Afatinib With CT and RT for EGFR-Mutant NSCLC | active not recruiting | Phase 2 | 19 | Massachusetts General HospitalOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06632262 | A Phase 2 Clinical Study of ABSK061 and ABSK043 | recruiting | Phase 2 | 202 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06269211 | Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression(TOPLINE) | recruiting | Phase 2 | 29 | Ruijin HospitalOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT04787042 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | recruiting | Phase 1 / Phase 2 | 316 | Simcha IL-18, Inc.INDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT05199272 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | active not recruiting | Phase 1 / Phase 2 | 141 | 23andMe, Inc.INDUSTRY | 2 | Nov 15, 2024 | clinicaltrials |
| NCT06690671 | A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC | not yet recruiting | Phase 1 / Phase 2 | 30 | Shanghai Chest HospitalOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06688656 | Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC(Peri-E) | not yet recruiting | Phase 2 | 30 | Shanghai Chest HospitalOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06589778 | A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 124 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06388031 | ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI | recruiting | Phase 2 | 27 | Peking Union Medical College HospitalOTHER | 1 | Nov 7, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 20, 2025source: clinicaltrials